British Journal of Haematology · 2014 · 93 citations · 33 references
MedicineOncologyPharmacotherapyChemotherapyHematologic OncologyMedical OncologyCancer ImmunotherapyChemotherapy In Hematologic MalignanciesChemotherapy Toxicity ManagementHematologic Malignancy TherapySupportive Care In CancerToxicity ManagementAdult Hematologic Malignancy ChemotherapyChemotherapy Dose IntensityClinical RemissionComplete Response AssessmentLymphoma ChemotherapyLymphoma Treatment ResponseNeurological Adverse EventsRituximab-based Therapy
To improve long-term outcomes for Burkitt leukaemia/lymphoma (BL) or aggressive lymphomas in adults, we assessed the benefit of adding rituximab and filgrastim support to a dose-dense modified chemotherapy regimen from the Cancer and Leukemia Group B (CALGB) 9251 trial. One hundred and five patients (aged 19-79 years) were enrolled; 27% were >60 years old; 47% had high or high-intermediate risk by International Prognostic Index (IPI) criteria. Common severe toxicities included stomatitis/upper gastrointestinal toxicity (69%), renal insufficiency (10%), neurological events (25%) and pulmonary events (18%). Seven died from treatment-related causes (one central nervous system bleed, four infections, two respiratory failure); five were >60 years old. Results in this adult population are encouraging as complete response (CR) was observed in 83% and 4-year event-free (EFS) and overall survivals (OS) were 74% and 78%, respectively. Results compare favourably to our prior chemotherapy alone study (CALGB 9251) but despite this, high-risk patients still had worse outcomes. In conclusion, short duration, intensive chemo-immunotherapy is feasible and should be considered in adults with BL as it results in high remission rates and durable remissions.
33
A Predictive Model for Aggressive Non-Hodgkin's Lymphoma
New England Journal of Medicine · 1993 · 5K citations · Full text
Medicine, Oncology, Chemotherapy +15
Revised Response Criteria for Malignant Lymphoma
Bruce D. Cheson, Beate Pfistner, Malik E. Juweid et al. · Journal of Clinical Oncology · 2007 · 4.4K citations · Full text
A predictive model for aggressive non-Hodgkin's lymphoma
Margaret A. Shipp, David P. Harrington, J R Anderson et al. · 1993 · 3.5K citations
Medicine, Oncology, Chemotherapy +15
Nancy L. Harris, Elaine S. Jaffe, J Diébold et al. · Journal of Clinical Oncology · 1999 · 3.3K citations
Medicine, Hematology, Pathology +17
The Statistical Analysis of Failure Time Data
Walter R. Young · Journal of Quality Technology · 1981 · 1.7K citations